Compare abrdn Income Credit Strategies Fund (ACP) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Biogen Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Biogen Inc trades at $203.5 (market cap $30.37B). The key difference: Biogen Inc is far larger — about 46.3× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ACP | BIIB | |
|---|---|---|
Market Cap | $656.21M | $30.37B |
Sector | Financials | Health |
52-Week High | $5.98 | $216.63 |
52-Week Low | $5.01 | $122.68 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $32.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Biogen (BIIB) trades at $205.70, down 4.82% today, with a bullish technical signal and strong earnings beat history. The stock shows solid fundamentals with a P/E of 22.42, net income margin of 13.81%, and positive cash flow trends. Recent acquisitions like RayThera for up to $1 billion aim to expand its immunology pipeline, while Alzheimer's portfolio updates at AAIC 2026 provide near-term catalysts. Analyst consensus is bullish with a $224.82 price target, though legal investigations and legacy drug sales declines pose headwinds.
The outlook remains positive given earnings momentum and strategic pipeline investments, but investors face risks from ongoing legal probes and competitive pressures. The stock offers upside to consensus targets if new drug launches offset revenue declines, but volatility may persist amid sector rotation and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
